Treatment options in patients with systemic sclerosis-associated interstitial lung disease
Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate.
by The Lancet Respiratory Medicine
The podcast In conversation with... is embedded on this page from an open RSS feed. All files, descriptions, artwork and other metadata from the RSS-feed is the property of the podcast owner and not affiliated with or validated by Podplay.